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Summary
 
The 
 
b
 
2 family of integrins, CD11a, CD11b, CD11c, and 
 
a
 
d, are expressed on most leuko-
cytes. We show that the newest member of this family, 
 
a
 
d, is expressed on human eosinophils
in peripheral blood, and surface expression can be upregulated within minutes by phorbol ester
or calcium ionophore A23187. Culture of eosinophils with interleukin 5 (IL-5) leads to a two-
to fourfold increase in 
 
a
 
d levels by 3–7 d without a change in 
 
a
 
4 integrin expression. Eosino-
phils isolated from late phase bronchoalveolar lavage fluids express 
 
a
 
d at levels similar to that
seen after 3 d of IL-5 culture. Regarding 
 
a
 
d
 
b
 
2 ligands, in both freshly isolated and IL-5–cul-
tured eosinophils, as well as 
 
a
 
d
 
b
 
2-transfected Chinese hamster ovary cells, 
 
a
 
d
 
b
 
2 can function
as a ligand for vascular cell adhesion molecule 1 (VCAM-1). This conclusion is based on the
ability of monoclonal antibodies to 
 
a
 
d, 
 
b
 
2, or VCAM-1 to block cell attachment in static ad-
hesion assays. In experiments with eosinophils, the relative contribution of 
 
a
 
d
 
b
 
2 integrin–
mediated adhesion is enhanced after IL-5 culture. These experiments demonstrate that 
 
a
 
d
 
b
 
2 is
an alternative ligand for VCAM-1, and this integrin may play a role in eosinophil adhesion to
VCAM-1 in states of chronic inflammation.
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E
 
osinophils have been shown to play an important role
in a variety of inflammatory diseases (1). Besides their
postulated importance in parasitic infections, these cells are
felt to participate in the pathogenesis of allergic disease. In
asthma, for example, eosinophils are selectively recruited
into the lung, where release of their products, such as gran-
ule proteins and leukotrienes, contributes to the airway
damage seen in asthma (2, 3). Indeed, one of the possible
mechanisms by which corticosteroids work in asthma is
that they substantially decrease eosinophil numbers both in
the lung and peripheral circulation (4, 5).
Integrins are a class of heterodimeric surface molecules
involved in cellular adhesion (6). They are expressed on
leukocytes and other cells, and are composed of both an 
 
a
 
and a 
 
b
 
 chain. Based on shared 
 
b
 
 subunits these molecules
can be classified into families. Eosinophils express members
of the 
 
b
 
1, 
 
b
 
2, and 
 
b
 
7 integrin families, and in many re-
spects their integrin expression resembles that of other leu-
kocytes (7). However, because human eosinophils express
 
a
 
4
 
b
 
1 and 
 
a
 
4
 
b
 
7 integrins, but normal human neutrophils
do not, their interaction with one of their ligands, vascular
cell adhesion molecule 1 (VCAM-1),
 
 
 
is felt to be a mech-
anism by which selective recruitment of eosinophils into
sites of allergic inflammation occurs (8–10).
Recently a fourth 
 
b
 
2 integrin, 
 
a
 
d
 
b
 
2, was identified
and found to be most homologous to CD11b/CD18 and
CD11c/CD18 (11). 
 
a
 
d
 
b
 
2 is expressed on most human
leukocytes, including neutrophils, monocytes, and, to a
lesser extent, lymphocytes (11). Van der Vieren et al., using
 
a
 
d
 
b
 
2-expressing chinese hamster ovary (CHO) transfec-
tants, demonstrated binding of 
 
a
 
d
 
b
 
2 to a human intercel-
lular adhesion molecule 3 (ICAM-3) chimeric protein (11).
Whether 
 
a
 
d
 
b
 
2 is expressed on eosinophils, and how it
functions on these cells, were not examined.
The goal of these studies was to examine the expression
and function of 
 
a
 
d
 
b
 
2 integrins on human eosinophils. We
report that eosinophils express 
 
a
 
d
 
b
 
2, that its surface ex-
pression can be acutely and chronically regulated by various
stimuli, and that, like 
 
a
 
4 integrins, they can function as a
ligand for VCAM-1.
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Materials and Methods
 
Reagents.
 
The following murine IgG
 
1
 
 mAbs were used: irrel-
evant control IgG
 
1
 
 mAb (Coulter Corp., Hialeah, FL), CD11a
mAb (MHM24; courtesy of Dr. James Hildreth, Johns Hopkins
University School of Medicine, Baltimore, MD [12]), CD11b
mAb (H4C2, Dr. Hildreth [13]; and clone 44, R&D Systems,
Minneapolis, MN), CD11c mAb (BU-15; Immunotech, Inc.,
Westbrook, ME), 
 
a
 
d mAb (169A, nonblocking, used for flow
cytometry [11]; and 240I, used in adhesion assays because of its
blocking ability [our unpublished observations]), CD18 mAb
(H52, Dr. Hildreth [14]; and 7E4, Immunotech, Inc.), 
 
a
 
4
(CD49d) mAb (HP2/1; Immunotech, Inc.), CD16 mAb (3G8;
Medarex, Inc., Annandale, NJ), and blocking F(ab
 
9
 
)
 
2
 
 anti–
VCAM-1 mAb (IG11b1; Caltag Laboratories, Inc., Burlingame,
CA). Also used was an IgG
 
2a
 
 FITC–anti-CD9 mAb (3B5;
Coulter Corp.), polyclonal human IgG (Sigma Chemical Co., St.
Louis, MO), R-PE–conjugated F(ab
 
9
 
)
 
2 
 
goat anti–mouse IgG
(BioSource International, Camarillo, CA), murine polyclonal IgG
(Sigma Chemical Co.), and FITC-conjugated polyclonal goat
anti–human IgE (Kirkegaard & Perry, Gaithersburg, MD). Solu-
ble recombinant human VCAM-1 and E-selectin (R&D Systems,
Inc.) and BSA (Sigma Chemical Co.) were also purchased.
The following stimuli were used: PMA and calcium ionophore
A23187 (Sigma Chemical Co.). Several C-C chemokines were also
used, including macrophage-derived chemokine (MDC; Gryphon
Sciences, South San Francisco, CA), RANTES (regulated upon
activation, normal T cell expressed and secreted), and Eotaxin
(R&D Systems, Inc.).
 
Cell Isolation.
 
Normodense (specific gravity 
 
$ 
 
1.090) eosino-
phils were isolated from peripheral blood of allergic volunteers by
density gradient centrifugation, hypotonic erythrocyte lysis, and
immunomagnetic negative selection as described previously, while
neutrophils were purified from peripheral blood of normal volun-
teers using density gradient centrifugation and hypotonic erythro-
cyte lysis alone (15, 16). Respective purities always exceeded 95%.
Enrichment of peripheral blood for basophils was performed using
a double-percoll density gradient separation, increasing the num-
ber of basophils to 3–10% of the total leukocyte count (17).
In some experiments, purified eosinophils were cultured for up
to 7 d in RPMI 1640 (Biofluids, Inc., Rockville, MD) with 1%
 
l
 
-glutamine, 10% fetal bovine serum (FBS), 100 U/ml penicillin,
100 
 
m
 
g/ml streptomycin, 500 ng/ml amphotericin (GIBCO
BRL, Gaithersburg, MD), supplemented with 10 ng/ml recom-
binant human IL-5 (R&D Systems, Inc.) as described (18). Via-
bility after 1 d or less of culture was 
 
$
 
95%, whereas viability by 7 d
was 80 
 
6 
 
1% (mean 
 
6 
 
SEM). Culture preparations in which
 
#
 
50% of cells were viable were excluded from analysis (5 of 42
experiments). In other experiments, eosinophils were incubated
with optimal concentrations of various stimuli (50 ng/ml PMA
or calcium ionophore A23187, 100 nM MDC, 100 ng/ml
RANTES, or 100 nM Eotaxin in PBS/0.1% BSA) for up to 15
min at 37
 
8
 
C.
Bronchoalveolar lavage (BAL) cells were obtained from allergic
patients who had undergone an endobronchial segmental allergen
challenge with either ragweed or 
 
Dermatophagoides pteronyssinus
 
 ex-
tract 18 h previously as described elsewhere (19). Eosinophil purity
in the late phase BAL fluid was 19 
 
6 
 
4% (mean 
 
6
 
 SEM,
 
 n 
 
5 
 
5).
 
CHO Transfectants.
 
CHO cells were transfected with both
the human 
 
a
 
d and 
 
b
 
2 integrin chains as described previously
(11). 
 
a
 
d
 
b
 
2-transfected CHO cells were cultured in DMEM/F12
media with 1 mM pyruvate and 2 mM 
 
l
 
-glutamine (Biofluids,
Inc.) supplemented with 10% dialyzed FBS, 100 U/ml penicillin,
100 
 
m
 
g/ml streptomycin, and 600 
 
m
 
g/ml G418 (all from GIBCO
BRL). Transfected CHO cells that failed to maintain their 
 
a
 
d
 
b
 
2
integrin expression with serial passage were used as controls.
 
Flow Cytometry.
 
Expression of integrins on the CHO cell
transfectants or on freshly isolated cells from blood after stimula-
tion or culture was evaluated using single color indirect immuno-
fluorescence and flow cytometry as described previously (17, 18).
Dual color detection of basophils (using anti-IgE) and lower pu-
rity eosinophils in BAL fluids (using anti-CD9) was also per-
formed. All samples were fixed in 1% paraformaldehyde (Sigma
Chemical Co.) and analyzed using a flow cytometer (EPICS Pro-
file II; Coulter Corp.). Approximately 10,000 events were col-
lected and displayed on a 4-log scale, yielding values for mean
fluorescence intensity (MFI).
 
Adhesion Assays.
 
For eosinophils, both freshly purified and
cultured, 
 
51
 
Cr-labeled cell adhesion to VCAM-1 (250 ng/ml) or
BSA (1%)–coated wells was performed for 30 min at 37
 
8
 
C as de-
scribed previously (20). In some experiments, cells were preincu-
bated for 30 min at 4
 
8
 
C with saturating concentrations of one or
more of the following blocking mAbs before examining their ad-
hesion: CD18 (7E4), CD11a (MHM24), CD11b (clone 44),
CD11c (BU-15), 
 
a
 
d (240I), and 
 
a
 
4 integrin (HP2/1).
For transfected and control CHO cells, adhesion was per-
formed using coated plates identical to those used for eosinophil
adhesion. However, because the interaction between CHO trans-
fectants and VCAM-1 was not as strong as that between eosino-
phils and VCAM-1 (data not shown), a modification of a previ-
ously described (21) gentle washing technique was used. This
technique allowed nonadherent cells to be dislodged from the in-
verted plate at 1 
 
g
 
 for 30 min at 20
 
8
 
C. Remaining adherent cells
were then removed using 0.1 M EDTA (Sigma Chemical Co.)
and counted by flow cytometry. Percent adhesion was deter-
mined from the number of adherent cells compared with the total
number of cells added. In addition to VCAM-1, E-selectin (100
ng/ml) was also used to coat wells in some adhesion experiments.
Besides the blocking mAbs used in the eosinophil studies, in cer-
tain experiments plates were pretreated with an appropriate dilu-
tion of F(ab
 
9
 
)
 
2
 
 anti–VCAM-1 mAb before the addition of CHO
cells.
 
Statistical Analyses.
 
Statistical analyses were performed using
an analysis of variance (ANOVA) with a Fisher post hoc 
 
t
 
 test.
Significance was set at
 
 P 
 
, 
 
0.05 for all tests.
Results
Expression of ad Integrins on Human Granulocytes and Regu-
lation of Its Surface Expression on Human Eosinophils. Using
indirect immunofluorescence and flow cytometry, eosino-
phils were found to consistently express all four of the b2
integrins, including adb2, with the rank order of MFI values
as follows: IgG control (3) , CD11c (15) , ad (22) , a4
(42) , CD11a (88) , CD11b (111) (values in parentheses
representative of n 5 7). Eosinophils and neutrophils had
roughly similar levels of ad expression, whereas basophils
had approximately twice the levels of surface expression (n 5
4, data not shown).
Subsequent studies were performed to determine whether
eosinophils could rapidly mobilize intracellular stores of
adb2 as has been reported for neutrophils (11). Purified
peripheral blood eosinophils were incubated for 15 min
with either PMA or the calcium ionophore A23187, and2189 Grayson et al. Brief Definitive Report
the surface expression of several a chains of the b2 inte-
grins was then measured by indirect immunofluorescence.
Fig. 1 shows the kinetics of this upregulation with phorbol
ester. Both PMA (50 ng/ml) and calcium ionophore (1
mM, data not shown) significantly increased the expression
of  ad integrin and CD11b. Within minutes of adding
PMA, expression increases, reaching significantly increased
levels by 10 min. Therefore, eosinophils appear to have
preformed stores of adb2 which, similar to CD11b stores,
can be rapidly mobilized to the cell surface. Other eosino-
phil-active stimuli were tested for their acute effects on
adb2 expression. Incubation of eosinophils for 15 min
with MDC (100 nM), IL-5 (10 ng/ml), RANTES (100
ng/ml), and Eotaxin (100 nM) failed to alter ad integrin
expression (data not shown).
Many eosinophil responses can be enhanced by pro-
longed exposure to certain cytokines, such as IL-5, a phe-
nomenon referred to as “priming” (22). Therefore, we de-
termined whether eosinophil culture with IL-5 would lead
to changes in surface expression of ad integrin. The kinet-
ics of this effect on ad integrin expression is shown in Fig.
2. As can be seen, the level of ad integrin increases gradu-
ally, with statistically significant increases in levels at days
4–7 of culture. In contrast, levels of a4 integrin did not
change significantly. Because late phase BAL eosinophils
express many characteristics of cytokine-primed eosino-
phils (19, 23), their levels were also compared. Indeed, late
phase BAL eosinophils also showed a statistically significant
increase in the level of ad integrin expression, with levels
similar to those seen after 3 d of culture in IL-5 (Fig. 2,
right).
Eosinophil adb2 Integrin Binds to VCAM-1. Although  ad
integrin has been shown to bind ICAM-3 and mediate leu-
kocyte–leukocyte adhesion (11), the next series of experi-
ments were designed to examine other possible ad ligands
for eosinophils. In part because of previous studies suggest-
ing b2 integrin–dependent, CD11b-independent eosino-
phil adhesion to VCAM-1 (20; and our unpublished obser-
vations), initial studies were performed using immobilized
recombinant VCAM-1.
As shown in Fig. 3 A, freshly isolated eosinophils ad-
hered to VCAM-1, and mAb blockade of a4 integrin ef-
fectively inhibited adhesion, whereas CD11b blockade had
no effect. However, adhesion could also be significantly
and consistently inhibited by the ad mAb 240I, albeit to a
lesser degree (z30% inhibition). Even more striking were
results of VCAM-1 adhesion experiments in which IL-5–
cultured eosinophils were used. Data in Fig. 3 B show that
under these conditions, mAbs to CD18, ad, or a4 inte-
grins were equally effective in reducing adhesion to back-
ground levels, whereas a combination of blocking mAbs to
CD11a, CD11b, and CD11c had no effect. Note also that
IL-5–cultured eosinophils displayed enhanced background
adhesion and reduced VCAM-1 adhesion compared with
those seen with freshly isolated eosinophils.
To further verify that adb2 functions as a ligand for
VCAM-1, we generated CHO transfectants expressing the
human ad and b2 integrin chains and used them in adhe-
sion assays. These transfected cells, unlike the control CHO
cells, expressed both the ad and b2 integrin chains at levels
similar to that on eosinophils (depending on passage num-
ber: an MFI for each subunit of 10–50, compared with an
MFI using an irrelevant IgG control mAb of 0.4–1.0; n 5
5). Transfected CHO cells expressing adb2 adhered to
VCAM-1–coated wells (16.0 6 3.6% adhesion, mean 6
Figure 1. Expression of both
ad integrin (squares) and CD11b
(circles) is upregulated rapidly in
peripheral blood eosinophils in-
cubated with PMA (50 ng/ml;
filled symbols) but not with buffer
alone (open symbols). Values are
expressed as average MFI 6
SEM, n 5 3. Irrelevant isotype
control antibody fluorescence
(1.7 6 0.2) was unchanged
throughout these experiments.
*P  ,  0.05 for treated vs. un-
treated samples.
Figure 2. Kinetics of changes in surface expression of ad (black bars)
versus a4 (white bars) integrins on eosinophils cultured with 10 ng/ml of
IL-5. Levels on eosinophils obtained from late phase BAL fluid after aller-
gen challenge are also displayed. Values are expressed as net MFI values
after subtraction of the irrelevant IgG1 control MFI values (3.1 6 0.2,
range 0.6–5.7). *P , 0.05 vs. day 0 value, n $ 3.
Figure 3. Adhesion of freshly isolated (A, n $ 5) or IL-5–cultured (10
ng/ml for 4–7 d; B, n $ 3) eosinophils to immobilized recombinant
VCAM-1. Blocking mAbs used included MHM24 (CD11a), clone 44
(CD11b), BU-15 (CD11c), 7E4 (CD18), 240I (ad integrin), and HP2/1
(a4 integrin). Results represent mean 6 SEM for percent adhesion; *P ,
0.05 vs. VCAM-1 adhesion without mAb, ‡P , 0.05 vs. VCAM-1 adhe-
sion in the presence of mAb 240I.2190 adb2 on Eosinophils Binds VCAM-1
SEM; n 5 11), and adhesion was effectively blocked by an
F(ab9)2 mAb against the first domain of VCAM-1 (80.1 6
5.2% inhibition; P , 0.0005 vs. adb2-transfected CHO
cell adhesion to VCAM-1, n 5 3) as well as by mAbs (n 5
3) against either CD18 (79.8 6 18.1% inhibition; P ,
0.0005) or ad integrin (59.6 6 21% inhibition; P ,
0.001). In contrast, control nontransfected CHO cells failed
to adhere to VCAM-1 (1.9 6 0.9% adhesion; n 5 3), and
neither the transfected nor the control CHO cells displayed
significant adherence to wells coated with another adhesion
protein, E-selectin (6.1 6 3 and 1.5 6 0.5% adhesion re-
spectively, n 5 2–5).
Discussion
These studies have shown that adb2, like other b2 inte-
grins, is expressed on human eosinophils, basophils, and
neutrophils. On peripheral blood eosinophils, the level of
ad integrin expression is similar to that of a4 integrins,
greater than that of CD11c, and less than that of CD11a
and CD11b. Stimuli such as PMA and the calcium iono-
phore A23187 rapidly upregulated eosinophil surface ex-
pression of ad integrins, whereas a more gradual increase in
surface expression was seen after 4–7 d of culture in media
containing IL-5. In adhesion assays, adb2 integrin was
shown to function as a ligand for VCAM-1 in both freshly
isolated and IL-5–cultured eosinophils; these results were
corroborated in adhesion assays using adb2-transfected CHO
cells. Based on mAb blocking studies with freshly isolated
eosinophils, adhesion to VCAM-1 was mainly mediated
through  a4 integrins, the other known ligand for VCAM-1.
However, in IL-5–cultured eosinophils, adhesion to
VCAM-1 was equally mediated by a4 and ad integrins.
Together, these data are the first to demonstrate activation-
dependent regulation of adb2 integrin expression and
function on human eosinophils and document a novel
function for eosinophil adb2 as an alternative ligand for
VCAM-1.
There appear to be preformed stores of ad integrin in
eosinophils, as evidenced by the rapid upregulation of
surface expression with exposure to PMA or calcium iono-
phore. These results are similar to those observed for ad
integrin and neutrophils (11). The kinetics of enhanced ex-
pression with PMA exposure was similar to that of CD11b,
suggesting that these two leukointegrins might exist in sim-
ilar or identical intracellular compartments. The location of
this compartment for either integrin in eosinophils is not
known; however, in neutrophils, preformed stores of
CD11b have been localized to specific granules (24, 25).
The immunolocalization of these preformed b2 integrin
pools, as well as effects of more physiologic activators of
eosinophils on integrin expression, are currently under in-
vestigation.
In contrast to the rapid mobilization by PMA, a gradual
increase in surface ad integrin expression was seen during
IL-5 culture. Whether this represents events occurring at
the level of transcription or translation, rather than slow
mobilization from preformed pools, is not yet known, due
in part to difficulties encountered in isolating eosinophil
mRNA as well as adverse effects of inhibitors of transcrip-
tion and translation on eosinophil survival. In examining
levels of ad integrin on late phase BAL eosinophils, which
have already undergone cell adhesion and migration to get
to the airway lumen, levels of expression intermediate to
those seen on freshly isolated and IL-5–cultured eosinophils
were observed. These data suggest that at least a portion of
the elevated levels of ad found after IL-5 culture are likely
due to increased transcription and translation of ad inte-
grin.
A particularly novel aspect of this study was the determi-
nation that adb2 integrin, expressed on eosinophils and
CHO transfectants, can function as a ligand for VCAM-1.
Although the exact binding site on VCAM-1 is unknown,
it is interesting that an mAb to the a4 integrin binding site
in the first domain of VCAM-1 completely blocked adb2
integrin–dependent VCAM-1 adhesion. While this sug-
gests that the adb2 binding site is near or identical to that
for a4 integrins, additional studies are required to examine
this issue more directly. Whether adb2 integrins can bind
to other a4 integrin ligands, such as fibronectin or mucosal
addressin cell adhesion molecule 1, is unknown. The find-
ing that adb2 integrin can function as a ligand for VCAM-1
appears to conflict with data presented in the first report
on human adb2 integrin by Van der Vieren et al. (11). In
that paper it was shown that these same adb2-transfected
CHO cells bound to a soluble ICAM-3 construct but not
to a VCAM-1–Ig chimeric protein. Possible explanations
for this discrepancy include a lower affinity for soluble
ligand binding as well as other differences in assays, such as
temperature.
Depending on the experimental conditions, both a4 and
ad integrins can mediate eosinophil adhesion to VCAM-1.
As we have shown in IL-5–cultured eosinophils, the rela-
tive contribution of ad integrin–dependent versus a4 inte-
grin–dependent adhesion increases in parallel with an in-
crease in ad integrin surface expression. However, because
regulation of integrin affinity also influences adhesive func-
tion, additional studies are needed to define the mecha-
nisms responsible for these IL-5–induced changes. Another
potential paradox from our findings is that although neu-
trophils express adb2, they do not adhere to seven-domain
VCAM-1. The most plausible explanation for this again
appears to be related to integrin activation state. Freshly
isolated eosinophils and neutrophils express similar levels of
ad integrins and, at least for eosinophils, much lower ad in-
tegrin–dependent adhesion responses than those seen with
activated cells. Whether this can be overcome with neutro-
phil activation is not yet known. Finally, the function of ad
integrin in vivo is currently under investigation. Based on
our results, it is plausible that because ad integrins on eosin-
ophils bind to VCAM-1 and are upregulated with IL-5 in
vitro and in BAL fluids in vivo, this leukointegrin may play
a role in cytokine-primed eosinophil recruitment to in-
flammatory sites. However, evaluation of this hypothesis
will require further investigation.2191 Grayson et al. Brief Definitive Report
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